Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07844915
NA

Artificial Intelligence Enhanced Remote Monitoring in Interstitial Lung Disease

Sponsor: King's College London

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn whether artificial intelligence AI-enhanced remote monitoring (AIRM) is feasible, safe and acceptable for adults with fibrotic interstitial lung disease (fILD). The artificial intelligence (AI) system uses information collected through home monitoring to identify patterns that may suggest a person's lung condition is getting worse. The AI does not make treatment decisions. Its outputs are reviewed by healthcare professionals. The main questions this study aims to answer are: Is AIRM feasible and acceptable for people with fILD and their healthcare professionals? Can it be used safely to help identify possible worsening of fILD? How well does the AI system identify clinical deterioration? Participants will take part for about 12 months. They will: Measure their lung function and oxygen levels at home each week using connected monitoring devices. Report their breathlessness and cough symptoms each week using the patientMpower app. Complete questionnaires about their health and their experience of remote monitoring at the start of the study and every 3 months. Continue to receive their usual clinical care. Some participants will also be invited to an interview or focus group to discuss their experience of AI-enhanced remote monitoring. Healthcare professionals involved in the study may also be invited to discuss their experience of using the system. The AI system is investigational and is being evaluated as part of this study. Healthcare professionals will review relevant AI-generated alerts before taking any clinical action. The AI will support, rather than replace, clinical judgement.

Official title: A Mixed-Methods Feasibility Study Evaluating Artificial Intelligence Enhanced Remote Monitoring in Interstitial Lung Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2026-12-01

Completion Date

2028-06-01

Last Updated

2026-09-28

Healthy Volunteers

No

Interventions

DEVICE

AIRM v1.0 AI-Enhanced Remote Monitoring

AI-enhanced remote monitoring (AIRM) delivered through the patientMpower platform for 12 months. Participants will use connected home spirometry and pulse oximetry devices and report symptoms and patient-reported measures. AIRM version 1.0 is an investigational artificial intelligence (AI) algorithm that analyses longitudinal multimodal remote monitoring data to identify patterns associated with potential clinical deterioration in fibrotic interstitial lung disease (fILD). AIRM-generated outputs that may contribute to clinical management will be reviewed by an appropriately qualified clinician before any clinical action is taken. The algorithm will remain fixed during the prospective study and will not be retrained or modified during participant follow-up. AIRM supports, rather than replaces, clinical judgement and usual clinical care.

Locations (1)

King's College London

London, United Kingdom